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MaThe left atrial appendage (LAA) has been identiﬁed as a predominant source of thrombus formation leading to signiﬁcant
thromboembolic events in patients with nonvalvular atrial ﬁbrillation. Medical therapy to eliminate thrombus formation
in the LAA has been the standard of care for several decades, but mechanical approaches designed to exclude the LAA
from the circulation have recently been developed. The largest body of randomized and nonrandomized data to date has
been for the Watchman device (Boston Scientiﬁc, Natick, Massachusetts), which was recently approved by the Food and
Drug Administration for selected patients in the United States. There are no current guidelines or guidance for institutions
and operators looking to become involved in this therapy. This perspective is aimed at exploring these issues and
providing necessary information and guidance to these programs and operators to help ensure a successful launch of
a LAA occlusion program and optimize patient selection, procedural performance, and outcome. (J Am Coll Cardiol
2015;65:2337–44) © 2015 by the American College of Cardiology Foundation.A trial ﬁbrillation (AF) is a common arrhythmiaencountered in clinical practice, with a prev-alence of 2 million in the United States; this
number is expected to increase to 16 million individ-
uals by 2050 (1). A major consequence of AF is throm-
boembolism, particularly ischemic stroke; the risk of
stroke in patients with AF is approximately 5% per
year (2). Oral anticoagulation with warfarin and novel
oral anticoagulant agents (NOACs) remain the corner-
stone of stroke prevention in AF; warfarin has been
shown to decrease the risk of stroke by as much as
65% (3), and the NOACs have similar efﬁcacy with
reduced risk of intracerebral hemorrhage.
Left atrial appendage (LAA) occlusion has emerged
as a safe and effective alternative to the use of oral
anticoagulation for stroke prevention in selected pa-
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TABLE 1 Possible Clinical Scenarios for LAA Occlusion With the
Watchman Device
1. As an alternative to oral anticoagulation in patients intolerant
of OACs
2. Patients with high stroke and concomitant high bleeding risk
3. Patients with thromboembolic events while on OACs with
therapeutic INR or on a NOAC and no other etiology for the
clinical event
4. Patients that can tolerate oral anticoagulation and are also
candidates for LAA device occlusion
5. Patients undergoing AF ablation or MitraClip implantation that may
qualify for concomitant LAA occlusion at the same time of the
original procedure
AF ¼ atrial ﬁbrillation; INR ¼ international normalized ratio; LAA ¼ left atrial
appendage; NOAC¼ novel anticoagulant agent(s); OAC¼ oral anticoagulant agent.
ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CT = computed tomography
DAPT = dual antiplatelet
therapy
EP = electrophysiologist
FDA = U.S. Food and Drug
Administration
IC = interventional cardiologist
ICE = intracardiac
echocardiography
LAA = left atrial appendage
NOAC = novel oral
anticoagulant agent(s)
OAC = oral anticoagulant
agent(s)
TEE = transesophageal
echocardiography
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2338POTENTIAL OPPORTUNITIES AND
BENEFITS OF LAA OCCLUSION
Although device-maker Boston Scientiﬁc
highlighted the “ﬁrst-of-its-kind alternative
to long-term warfarin” (Coumadin) in an-
nouncing the approval of the LAA occlusion
device (9), the indication was only for
patients with nonvalvular AF who are
at increased risk for stroke and systemic
embolism on the basis of CHADS2 (con-
gestive heart failure, hypertension, age
$75 years, diabetes mellitus, prior stroke or
TIA or thromboembolism) or CHA2DS2-VASc
(congestive heart failure, hypertension, age
#75 years, diabetes mellitus, prior stroke or
TIA or thromboembolism, vascular disease,
age 65 to 74 years, sex category) scores and
deemed by their physicians to be suitable forwarfarin, but who “have an appropriate rationale to
seek a nonpharmacological alternative to warfarin”
(10). Apart from this current indication, there are
several other possible indications for use of this
device:
Possible clinical scenarios (Table 1)
1. As an alternative to oral anticoagulation in pa-
tients intolerant to oral anticoagulant agents
(OACs). Current estimates suggest that up to 40%
of people with AF and an indication for OAC have
a relative or absolute contraindication to the use
of warfarin, and <50% of eligible patients are
being treated because of medication intolerance or
noncompliance (10–13). Whether this pattern of
underutilization will be similar with the several
new OACs that are now approved is unknown.
These agents have their own unique concerns,
such as continued issues with gastrointestinal
bleeding, cost, lack of antidotes, and for some of
them, the need for twice-a-day dosing. Patients
with previous intracranial bleeds, recurrent gas-
trointestinal bleeds, coagulopathies, and intoler-
ance to NOACs/warfarin will still present clinical
challenges. Unfortunately, there is a lack of ran-
domized clinical trial data for use of the LAA oc-
clusion device in these patients. The most robust
data available for LAA device occlusion in this
group comes from the European PLAATO (Percu-
taneous Left Atrial Appendage Transcatheter Oc-
clusion) study (14) and the ASAP (Aspirin Plavix
Feasibility Study with WATCHMAN Left Atrial
Appendage Closure Technology) registry (15). In
the ASAP registry, the predicted stroke rate
depending on the CHADS2 score was 7.3% per yearand the observed stroke rate was 2.3%. It must be
pointed out that these patients were on dual an-
tiplatelet therapy (DAPT) for a duration of
approximately 6 months and on aspirin indeﬁ-
nitely thereafter. Potential patients who would be
enrolled into this pathway must be able to tolerate
short-term DAPT and indeﬁnite use of aspirin.
2. Patients with high stroke and concomitant high
bleeding risk. A HAS-BLED (Hypertension, Ab-
normal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR [International
Normalized Ratio], Elderly, Drugs/Alcohol Con-
comitantly) score $3 would suggest a high
bleeding risk (16,17). In these cases, individual
patient-level assessment is warranted to accu-
rately quantify the stroke and bleeding risk; a trial
of warfarin or NOACs may still be warranted,
especially if the risk of intracranial hemorrhage is
relatively low. Patients with high stroke risk, but
unacceptable bleeding risk, should be considered
for LAA device occlusion. Similarly, patients on
triple anticoagulant therapy (DAPT and an OAC
drug), such as those with atrial ﬁbrillation who
receive a drug-eluting stent, have an elevated
bleeding risk; they may be considered for LAA
device occlusion. Finally, patient subgroups with
comorbidities associated with a high bleeding risk
not captured by the HAS-BLED score, such as ma-
lignancy and inﬂammatory bowel disease, may
also be considered for LAA device occlusion.
3. Patients with thromboembolic events while on
OACs with therapeutic international normalized
ratio or on a NOAC when no other etiology for the
clinical event can be identiﬁed. In this group, LAA
device occlusion may potentially be used as an
adjunct to anticoagulation.
4. Patients that can tolerate oral anticoagulation and
are also candidates for LAA device occlusion. This
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2339is the group in which the randomized clinical trial
was conducted. On the basis of the randomized
trial results, LAA device occlusion is noninferior to
warfarin therapy and appears to be a safe alterna-
tive to warfarin in these patients. This has been
proven in the initial trials of this device and in
long-term follow-up studies. Holmes et al. (4)
published the initial PROTECT AF (Watchman
Left Atrial Appendage System for Embolic Protec-
tion in Patients with AF) trial that documented the
noninferiority of device occlusion using the
Watchman device compared with oral anticoagu-
lant therapy with warfarin. A recently published
long-term follow-up study on this group of pa-
tients revealed continued noninferiority of LAA
occlusion with the Watchman device, as compared
with warfarin (8). Concerns about the early pro-
cedural safety events seen in the initial PROTECT
AF study were alleviated in the second randomized
study, the PREVAIL trial, which revealed signiﬁ-
cant reductions in periprocedural events/compli-
cations (7). This would be a rather large population
and issues of cost effectiveness, device safety, and
efﬁcacy when compared with the NOACs would be
important here. In these patients, the risks and
beneﬁts of anticoagulant agents and LAA device
occlusion should be presented so that they can
make well-informed decisions regarding their
preferred therapeutic option.
5. Patients with atrial ﬁbrillation undergoing AF
ablation or MitraClip procedures—here, LAA oc-
clusion can be an adjunct procedure while these
other procedures are being performed. A recent
paper by Swaans et al. (18) revealed that LAA oc-
clusion with the Watchman device and AF ablation
can be successfully and safely combined. Patients
with signiﬁcant mitral insufﬁciency and AF un-
dergoing the MitraClip (Abbott Vascular, Santa
Clara, California) procedure may also plausibly
beneﬁt from concomitant LAA occlusion at the
time of the MitraClip procedure. A recent case
report documented the ﬁrst combined LAA occlu-
sion and MitraClip implantation (19). Pros and cons
of this combined procedure are numerous: it may
be cost effective and provide the dual beneﬁts to
the patient; however, it may expose the patient to
potential complications of both approaches and
may result in somewhat prolonged procedure and
ﬂuoroscopy times.
Outside of the United States, LAA device occlusion
is being performed (20–26). The current European
Society of Cardiology guidelines on AF (20) recom-
mend that LAA closure may be considered in patientswith high stroke risk, but with contraindications for
long-term oral anticoagulation (Class IIb recommen-
dation). On the basis of this recommendation, the
European Heart Rhythm Association and the Euro-
pean Association of Percutaneous Cardiovascular
Interventions drafted the ﬁrst European consensus
statement on catheter-based LAA occlusion (21). This
document provides guidance for clinicians in Europe
regarding evaluation and management of thrombo-
embolic protection in patients with AF. A recent Eu-
ropean survey examined data from 24 centers that
performed LAA occlusion procedures. In this survey,
the majority of procedures were performed by inter-
ventional cardiologists (ICs) and each center per-
formed an average of 10.6  11.7 (range 1 to 50) LAA
procedures per year. The most common indication
was “patient has absolute contraindication to long-
term anticoagulants.” Complication rates varied
widely, but included pericardial tamponade (1% to
10%), major bleeds (0% to 8%), thromboembolism
(0% to 10%), and device dislodgement (0% to 5%).
The majority of the centers (65%) reported a 0%
complication rate.
The Amplatzer Cardiac Plug is the other commonly
used endocardial LAA occlusion device. Data on
this device have been limited to single-center
studies, case series, and small registries (22–25).
The largest clinical study to date on the use of the
Amplatzer Cardiac Plug (St. Jude Medical, Minneap-
olis, Minnesota) for LAA device occlusion was
recently published by Tzikas et al. (25), who analyzed
1,047 patients from 22 centers. These investigators
reported a 97.3% success rate with a 1-year all-cause
mortality of 4.2%. There was a 59% risk reduction
in thromboembolism and a 61% risk reduction in
bleeding events. The Central Illustration illustrates
the clinical pathways for potential patients for LAA
occlusion.
OPERATORS/PERSONNEL/
INSTITUTIONAL CONSIDERATIONS
Similar to other structural heart procedures, LAA de-
vice occlusion will beneﬁt from a multidisciplinary
team approach to maximize program success. ICs
with structural heart training experience and elec-
trophysiologists (EPs) with training and experience in
performing AF ablation both have an interest in per-
forming this procedure. Each group brings a different
skill set that should be used in a collaborative fashion
to maximize procedural safety and efﬁcacy. As pro-
cedures are planned and performed with echocar-
diographic guidance, cardiac imaging specialists will
be essential members of the team. We suggest a
CENTRAL ILLUSTRATION Potential Patients for Left Atrial Appendage Occlusion
Nonvalvular atrial fibrillation patients
Candidates for left atrial appendage closure therapy (If anatomic suitability and risk benefit ratio is fully explored)
Increased thromboembolic risk
(CHA2DS2−VASc ≥2)
with documented or presumed 
failure of warfarin or NOAC
Contraindication
to NOAC
or warfarin
Recurrent 
bleeding on
NOAC or warfarin
Intolerant
to NOAC
or warfarin
Persistent non-
compliance to 
NOAC or warfarin
Unwilling to take 
anticoagulant 
therapy
Increased thromboembolic risk
(CHA2DS2−VASc ≥2)
and increased bleeding risk
(HAS−BLED ≥3)
Alli, O. et al. J Am Coll Cardiol. 2015; 65(21):2337–44. 
Can tolerate anticoagulant agents
(novel oral anticoagulant agents [NOAC]
or warfarin) and are also candidates
for left atrial appendage closure
Prior stroke or
transient ischemic
attack whilst on
anticoagulant agents
Schema demonstrates the clinical pathways for potential patients for left atrial appendage occlusion. Adapted with permission from Camm et al. (26).
NOAC ¼ novel oral anticoagulant agent(s); LAAC ¼ left atrial appendage closure; TIA ¼ transient ischemic attack.
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2340collaborative approach, with ICs and EPs working
together in tandem, similar to current collaborations
between ICs and CV surgeons to ensure procedural
and institutional success and excellent patient out-
comes with transcatheter aortic valve replacement.
Although not all institutions have IC and EP exper-
tise, we believe that optimal care should involve both
specialties.
Speciﬁc training requirements must be met by
operators interested in performing this procedure,
regardless of their specialty: knowledge of LAA anat-
omy, experience with interpreting echocardiographic
images, and experience in performing transseptal
puncture and pericardiocentesis are all essential.
We recommend that operators and teams undergo
a rigorous, structured training program. This could be
provided by the relevant professional societies, as
well as by the device manufacturer, and would
include patient selection, adjunctive medications,
LA/LAA anatomy, speciﬁc device characteristics,
procedural techniques, and management of compli-
cations. Practical hands-on training would also be
important; this could involve simulators to practice
procedural steps and device deployment, as well as
live case demonstrations by experienced centers and
operators. Finally, we suggest that each team be
proctored for a minimum of approximately 5 to 10
cases, or until the team is comfortable with all aspectsof the procedure, device deployment, and recog-
nizing/managing complications.
Imaging experts with expertise in transesophageal
echocardiography (TEE) and computed tomography
(CT) imaging are also an invaluable part of the team.
TEE would be needed for pre-procedure assessment,
intraprocedural guidance, and post-procedure follow-
up. Personnel performing TEE for device occlusion
must be familiar with LAA anatomy, the procedure,
and required measurements for device selection and
delivery. We suggest a dedicated group of imagers
for this procedure; this may be the same group that
supports transcatheter aortic valve replacement and
percutaneous mitral valve repair procedures (some-
times called interventional echocardiography). They
should be familiar and experienced in supporting
procedures in the cardiac catheterization laboratory,
electrophysiology laboratory, or hybrid operating
rooms with real-time online imaging, particularly the
use of real-time 3-dimensional echocardiography.
These imaging specialists should also participate in
dedicated training sessions, with particular attention
paid to knowledge and techniques for acquisition
of baseline pre-procedural images, guidance during
device delivery, and post-procedural imaging.
Some of the barriers to having a dedicated imaging
specialist in each case have been reimbursement;
these procedures can be time-consuming and there is
FIGURE 1 Outline of the Evaluation and Therapy Process, as Patients Are Seen and Treated
May be done over the telephone
Can be performed by the nurse coordinatorPre-screening
•
•
Office visit
Appropriate Medical Records are reviewedConsultation
•
•
Includes TTE, TEE and CT imaging
Imaging
Studies
•
Performed under general anesthesia with intraprocedural TEE
Patients are discharged home on warfarin and aspirin for 45 daysProcedure
•
•
TEE is performed at this time
Assess device for residual leaks and thrombus formation
If no thrombus and no significant leaks around the device warfarin
is discontinued and clopidogrel is added to aspirin therapy
45-Day
Follow-up
Visit
•
•
•
Dual antiplatelet therapy is discontinued and patient is continued on aspirin6-Month
Follow-up
Visit
•
TEE may be performed at this time to check for thrombus formation
on the device on single antiplatelet therapy with aspirin
Aspirin is continued unless there are other indications to resume
warfarin therapy such as newly found thrombus on the device or in the left atrium
1-Year
Follow-up
Visit
•
•
High bleeding risk
CHADS-VASc Score >2AF Patient
•
•
AF ¼ atrial ﬁbrillation; CT ¼ computed tomographic imaging; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography.
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2342currently no adequate reimbursement for the time
spent by operators and echocardiographers in proce-
dural performance. In groups where productivity is
measured using relative value units, physicians
involved in this procedure may have to develop other
ways to account for the time spent supporting the
procedure (i.e., “virtual relative value units”).
Anesthesia support is another component of the
personnel team that must be involved with this pro-
cedure; traditionally, anesthesia support comes with
the operating room, but is becoming more frequent in
the cardiac catheterization and electrophysiology
laboratories due to the increasing number of pro-
cedures being performed in these laboratories that
require general anesthesia. To coordinate all the
groups and personnel involved and to optimize efﬁ-
ciency and safety, a dedicated LAA procedure day(s)
might be considered.
ALTERNATIVES TO
ENDOCARDIAL LAA OCCLUSION
The Lariat device (SentreHeart, Redwood City, Cal-
ifornia) is currently approved for use in the United
States for opposing tissue planes and has been uti-
lized for suture closure of the LAA; it combines both
endocardial and epicardial approaches. The PLACE-2
(Percutaneous Left Atrial Appendage Suture Ligation
Using the LARIAT Device in Patients with Atrial
Fibrillation) trial (6) was pivotal in documenting
the safety and efﬁcacy of the Lariat device. Use of
the Lariat device may also be incorporated into the
overall LAA occlusion program, because candidates
may beneﬁt from its use on the basis of anatomic
variation. By contrast, patients may not qualify for
use of the Lariat device because of previous cardiac
surgery, prior pericarditis, and/or a large and supe-
riorly directed LAA (>40 mm) in close proximity to
the left superior pulmonary vein. A potential beneﬁt
of the Lariat device is the ability of suture ligation
to aid in reduction of arrhythmia burden, which
may be useful in patients with recurrent AF
following ablation (27). Potential issues include
endothelial or pericardial trauma and the lack of
clarity on anticoagulation post-procedure. Using the
Lariat device in a recently published real-world
multicenter registry, Price et al. (28) documented
an 85% success rate and a 9.7% major complication
rate. There have not been any studies comparing
suture ligation with the Lariat device versus endo-
cardial LAA occlusion devices, and it is unclear if
such studies will be conducted, but real-world use of
both devices may shed some light on the efﬁcacy of
either strategy.Surgical LAA occlusion using sutures or staples at
the time of heart surgery (coronary artery bypass
graft, heart valve replacement) is also frequently
performed. The efﬁcacy of this procedure is being
evaluated in the ongoing LAAOS III (Left Atrial
Appendage Occlusion Study III) study (29), which will
follow patients undergoing surgical LAA occlusion at
the time of open-heart surgery over time to determine
the continued occlusion of the structure, efﬁcacy, and
safety outcomes.
PATIENTS/REFERRAL BASE/
TARGET POPULATION
The initial target population will depend on the
FDA-approved indication for use; once this is
formulated, several questions would need to be
addressed by operators/institutions. These include:
patient referral; where these patients would come
from; who will see them initially as outpatients; and
how will they move from the initial evaluation
period up until procedural performance. Patients
could be referred from several sources, (general car-
diology, primary care, hospitalists), and may need to
be seen in a dedicated clinic with a dedicated nurse/
clinic coordinator. There may be a large volume of
potential patients with a signiﬁcant “screen fail” rate,
and these patients would need be seen using a
streamlined, efﬁcient approach. One potential patient
ﬂow systemmight function as follows: an initial call to
scheduler or clinic coordinator to make arrangements
for the patient to be seen; the patient is seen by a
physician, either IC or EP, who screens for eligibility;
if the patient qualiﬁes, a pre-procedure TEE is
performed. If the patient is eligible, detailed risk/
beneﬁt sessions with the patient and family need
to be performed before performance of the planned
procedure.
The goal would be to perform this procedure in
appropriate patients who may beneﬁt from a device-
based strategy with high success rates and low
complication rates, avoiding patients who are too
sick, too old, or too frail, which may lead to high
complication rates.
IMAGING
Imaging remains central and essential to the devel-
opment of a successful LAA occlusion program. The
ability to assess the LAA using imaging modalities is
essential for pre-procedural assessment, during de-
vice delivery and deployment, and during follow-
up. The use of transthoracic and transesophageal
imaging techniques allow for adequate assessment
of the LAA. CT, magnetic resonance imaging, and
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2343intracardiac echocardiography (ICE) may also be
useful.
TEE remains the central imaging technique for
adequate visualization of the LAA; when used for pre-
procedural assessment, it is essential to demonstrate
adequate visualization to exclude LAA thrombus.
Adequate interrogation of the LAA is performed
using multiple views from 0 to 145, where LAA
morphology is adequately characterized, with mea-
surements of the LAA ostium and neck. Intra-
procedural imaging is also usually accomplished
using TEE; it aids with transseptal puncture, device
sizing and deployment, and detection of complica-
tions, such as pericardial effusion.
The accessibility of other imaging modalities, such
as ICE, is also important; occasionally patients may
not be able to undergo TEE or sedation under general
anesthesia. In such cases, ICE imaging may play an
important role. The ICE probe can be inserted directly
into the LA to obtain a closer imaging assessment of
the LAA, or it may be directed into the right ventricle
and the pulmonary artery, which also gives excellent
visualization of the LAA.
PROGRAM EVALUATION/
DATA COLLECTION/PATIENT FOLLOW-UP
This should be an ongoing effort between the admin-
istrative leadership and the clinical leadership;
assessment would include quality measures, out-
comes, length of stay, resource utilization, and cost
effectiveness. It would be beneﬁcial to develop a
standard methodology for assessment of periopera-
tive and post-operative complications, such as the
VARC 2 (30) criteria used for transcatheter aortic valve
replacement. Adequate data collection would be a
very important component of the program; a national
post-approval registry is currently being considered.
Regardless, individual institutions should track their
own data and continually assess and track their suc-
cess and complication rates. Maintenance of a post-
approval registry is extremely important, because it
enables collection of additional data that will shed
more light on device performance in the real world.
PRACTICAL CONSIDERATIONS
Incoming referrals to the center must be carefully
screened and evaluated before their appointment; a
screening checklist may be utilized to ensure that the
appropriate candidates are being selected for ap-
pointments. The initial clinic visit will include a
comprehensive history and physical examination, as-
sessment of stroke and bleeding risk, basic laboratory
testing, and review of imaging studies (transthoracicechocardiography, CT, and TEE, if performed). At
this visit, frailty assessment, quality of life metrics,
and mental status assessment may also be conducted.
Patients are likely to come into the facility before
the procedure, at which time, a history and physical is
performed, basic blood work is obtained, and risk–
beneﬁt considerations are discussed fully with the
patient and family. The goal of the procedure is the
successful delivery of a LAA occlusion device and
prevention/rapid management of potential compli-
cations. For the procedure, sedation and general
anesthesia is initiated, appropriate arterial and
venous lines are placed, and a TEE probe is inserted.
The procedure is then performed using standard
techniques with TEE imaging.
Post-procedure, patients can be managed in a car-
diac step-down unit; care is taken to ensure close
observation, with attention to blood pressure and
early detection of complications. Most patients would
be expected to spend between 1 and 2 days in the
hospital following an uncomplicated procedure; for
patients intolerant of OACs, DAPT with aspirin and
clopidogrel is used. Follow-up at 45 days is recom-
mended. At this visit, a TEE is performed to assess
device position, check for peri-device LAA ﬂow, and
assess device-related thrombus. Patients are seen at 6
months, when clopidogrel may be discontinued for
those who were on DAPT, and aspirin is continued
indeﬁnitely. Patients undergoing AF ablation or
MitraClip implantation along with concomitant LAA
occlusion may be referred from specialty AF or valve
clinics, but will follow a similar pathway post-
procedure as the general patient. Figure 1 provides a
schematic diagram of a typical patient pathway from
evaluation to therapy and follow-up.
CONCLUSIONS
LAA occlusion for stroke prevention in patients with
AF represents a tremendous opportunity to change
the landscape of stroke prevention in patients with
nonvalvular AF. Several devices have CE-mark
approval and the Watchman device was recently
approved in the United States. As we discussed, in
order to ensure success of the device/procedure, op-
erators/institutions must commit to a strong collab-
orative approach to optimize outcomes and resource
utilization.
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